OncBioMune Pharmaceuticals submitted an application with the Mexican equivalent of the US Food and Drug Administration to commercialize a licensed anti-rabies drug.
OncBioMune Pharmaceuticals (OTCQB:OBMP) submitted an application with the Mexican equivalent of the US Food and Drug Administration to commercialize a licensed anti-rabies drug.
As quoted in the press release:
The License Partner has granted OncBioMune an exclusive license for the anti-rabies drug for the Mexican market. The License Partner and product brand are being kept confidential for competitive reasons at this time.
The injectable anti-rabies immunoglobulin (human) is currently sold throughout the world, including Brazil, Argentina, Colombia and Peru. It is indicated for passive, transient post-exposure prophylaxis against rabies infection administered after exposure / contact with an animal suspected of being infected with rabies, a viral infection caused by viruses belonging to the Lyssavirus genus. The treatment has yet to be commercialized in Mexico.
“This is a popular anti-rabies therapeutic throughout South America and we are excited with the submission seeking to commercialize it in Mexico under the OncBioMune umbrella,” commented Manuel Cosme Odabachian, General Manager of Global Operations at OncBioMune. “Rabies prevalence in Mexico is quite high and we believe that we will able to be competitive in the bid/tender process to capture our fair share of market. We are optimistic that we will be selling the product in 2018 and estimate annual demand in the range of 10,000 to 20,000 units, making it a strong complement to our other revenue-generating assets.”